Abeona Therapeutics® Announces Participation in November Investor Conferences

Company Overview - Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [3] - The company is developing an investigational autologous, COL7A1 gene-corrected epidermal sheet, prademagene zamikeracel (pz-cel), for recessive dystrophic epidermolysis bullosa [3] - Abeona has a fully integrated cell and gene therapy cGMP manufacturing facility that supports the production of pz-cel for its Phase 3 VIITAL™ trial and is capable of commercial production upon FDA approval [3] - The company is also working on AAV-based gene therapies for ophthalmic diseases with high unmet medical needs, utilizing next-generation AAV capsids to improve tropism profiles for various diseases [3] Upcoming Events - Members of Abeona's management team will participate in the Truist Securities BioPharma Symposium on November 7, 2024, for investor meetings [1] - A fireside chat at the Stifel 2024 Healthcare Conference is scheduled for November 18, 2024, at 4:10 p.m. ET, along with additional investor meetings [1][2] - A live webcast of the fireside chat will be available on the Investors section of the Abeona website, with a replay accessible for a limited time [2]